熱門資訊> 正文
Nuvalent股票发行3.5亿美元，股价上涨19%
2024-09-16 19:22
- Clinical-stage biopharmaceutical company Nuvalent (NASDAQ:NUVL) commenced an underwritten public offering of $350M shares.
- There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Underwriters have a 30-day option to purchase up to an additional 15% of the shares.
- Shares of Nuvalent (NUVL) jumped 19% to $104 on Monday during pre-market hours of trade.
More on Nuvalent
- Nuvalent: Making Precise Progress In Its Oncology Pipeline
- Seeking Alpha’s Quant Rating on Nuvalent
- Historical earnings data for Nuvalent
- Financial information for Nuvalent
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
